# Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine

> **NCT05706324** · PHASE1 · UNKNOWN · sponsor: **Wuhan BravoVax Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation

## Key facts

- **NCT ID:** NCT05706324
- **Lead sponsor:** Wuhan BravoVax Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06
- **Primary completion:** 2023-12
- **Final completion:** 2024-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05706324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05706324, "Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05706324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*